Verve Therapeutics (VERV) announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its board of directors. Dr. Tatsis currently serves as executive vice president, chief regulatory and quality officer, of Vertex Pharmaceuticals (VRTX). Ms. Morrison currently serves as CEO and director of Q32 Bio (QTTB).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERV:
- Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics Announces New Chief Scientific Officer
- Verve Therapeutics Announces Leadership Update
- Verve Therapeutics CSO Andrew Bellinger steps down, Troy Lister to succeed